文献速递骨质疏松与代谢性骨病创伤骨科脊柱外科

系统性肥大细胞增多症中骨骼相关事件的管理与骨折预防

Management of skeletal-related events and fracture prevention in systemic mastocytosis.
PubMed 文献 · Osteoporos Int · 2025-11-20

系统性肥大细胞增多症(SM)常伴骨量丢失和骨折,尤其是椎体骨折。本综述讨论了SM骨表现的机制、骨折风险评估工具(BMD、FRAX、TBS)以及现有药物治疗(抗炎/肥大细胞稳定剂、抗骨质疏松药、减细胞药)。早期诊断和适当治疗可影响疾病结局及骨骼并发症。

要点

  • 年轻脆性骨折患者,尤其是椎体骨折,或不明原因低骨密度伴疑似SM症状/体征时,应排除SM。
  • 骨折预测可考虑危险因素并结合骨密度、FRAX和TBS值。
  • SM骨丢失的治疗包括抗炎/肥大细胞稳定剂、抗骨质疏松药和减细胞药。

核心结论

  • 通常早期诊断并给予适当治疗干预可影响该疾病及其骨骼相关并发症的结局。
  • 控制基础疾病通常最有效,但必要时需权衡每种治疗方案的获益与风险。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • SM常与骨量丢失相关,导致低骨密度(骨量减少或骨质疏松)和骨折,尤其是椎体骨折。
  • SM的其他骨表现包括骨痛、溶骨性病变甚至骨硬化。
  • SM骨丢失和骨损伤的推测机制包括血管活性介质和炎症标志物分泌、骨细胞释放的骨介质(如RANKL、OPG、硬化素和DKK1)以及肥大细胞肿瘤性浸润。
  • 骨折预测可通过考虑危险因素并使用骨密度、FRAX和TBS值来改善。
  • 高分辨率外周定量CT可能不可行,但提供更多信息。

关键数值与推荐

  • 识别脆性骨折危险因素(如高龄、男性、较低髋部BMD、增加的肥大细胞负荷或骨活检中的KIT突变)以检出SM高危患者,然后估计SM进展风险以确定骨丢失最佳药物类型。
  • SM本身的当前药物包括抗炎或肥大细胞稳定剂(酮替芬、色甘酸钠、抗组胺药、白三烯拮抗剂和抗IgE单克隆抗体)。
  • 抗骨质疏松药物(双膦酸盐、地舒单抗和特立帕肽)和减细胞药物(干扰素、化疗药物或酪氨酸激酶抑制剂)也用于治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic mastocytosis is a rare condition caused by the accumulation of abnormal mast cells (MC) in various organs, including the bone. The diagnosis of mastocytosis is sometimes challenging because of the incidence rate, the heterogeneity of clinical manifestations, and the varying sensitivity of diagnostic tools. While mastocytosis is an uncommon cause of osteoporosis, conversely, systemic mastocytosis (SM) is often associated with bone loss, resulting in low bone mineral density (osteopenia or osteoporosis) and fractures, particularly vertebral fractures. SM must be ruled out in young patients with fragility fractures, mainly vertebral fracture, or unexplained low bone mineral density accompanied by suspected SM symptoms or signs. Other bone manifestations of SM include bone pain, osteolytic lesions, and even osteosclerosis. The putative mechanisms of bone loss and damage in SM include the secretion of vasoactive mediators and inflammatory markers, bone mediators released from bone cells (osteoblast, osteoclast, and osteocyte) such as RANKL, OPG, sclerostin, and DKK1, and neoplastic infiltration of MCs. Usually, early diagnosis with appropriate therapeutic intervention can impact the outcome of this disease and its skeletal-related complications. Fracture prediction can be improved by considering risk factors and using bone mineral density, FRAX, and TBS values. High-resolution peripheral quantitative CT may not be feasible but provides more information. The first step is the detection of high-risk patients in SM by recognizing the risk factors for fragility fractures such as older age, male sex, lower hip BMD, increased mast cell mass, or KIT mutation in bone biopsies, and then estimating the risk of SM progression in order to determine the best type of medication for bone loss mastocytosis and for osteoporosis. The current medications for the treatment of mastocytosis itself include anti-inflammatory or mast cell stabilizers (ketotifen, cromolyn sodium, antihistamines, leukotriene antagonists, and anti-IgE monoclonal antibody). Anti-osteoporosis medications (bisphosphonates, denosumab, and teriparatide) and cytoreductive agents (interferon, chemotherapeutic agents, or tyrosine kinase inhibitors) are also used. Although controlling the underlying disease is usually most effective, the benefits and risks of each therapeutic approach should be balanced if needed.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Lunn EM, Lacount S, Greene LW, et al. Management of skeletal-related events and fracture prevention in systemic mastocytosis. Osteoporos Int. 2025. PMID: 41263967. doi:10.1007/s00198-025-07726-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。